Skip to content

Study · Systematic review · n = 304 · 2013

3 results

Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy.

Bakermans-Kranenburg MJ, van I Jzendoorn MH

Translational psychiatry21 May 2013Cited by 304 (Europe PMC)

PMID23695233 (opens in a new tab)PMCIDPMC3669921 (opens in a new tab)DOI10.1038/tp.2013.34 (opens in a new tab)PepBankPUB-23695233
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In 19 clinical trials across psychiatric disorders, oxytocin administration had a small combined positive effect (d=0.32).

    In plain wordsIn pooled trials of people with psychiatric disorders, oxytocin had a small combined benefit.

    Peptide
    Oxytocin
    Outcome
    IncreaseCombined effect of oxytocin across clinical disorders
    Study

    n = 304

    Outcome group
    Overall treatment effect · Mental health and mood
    Studied dose
    15 IU to more than 7000 IUAs given in this study (human).

    Measurements

    Combined effect size d
    0.32
    19 clinical trials

    Source sentences

    Summary
    The combined effect size was d=0.32 (N=304; 95% confidence interval (CI): 0.18-0.47; P<0.01).
    1 context sentence
    Summary · context
    In 19 clinical trials, covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress, the effects of OT administration were tested, with doses ranging from 15 IU to more than 7000 IU.
  2. 02HumanSystematic reviewEfficacy outcome

    In autism spectrum disorder, oxytocin administration had a significant combined effect (d=0.57).

    In plain wordsIn pooled trials of people with autism spectrum disorder, oxytocin had a moderate combined benefit.

    Peptide
    Oxytocin
    Outcome
    IncreaseCombined effect of oxytocin in autism spectrum disorder
    Study

    n = 68

    Outcome group
    Overall treatment effect · Mental health and mood
    Studied dose
    15 IU to more than 7000 IUAs given in this study (human).

    Measurements

    Combined effect size d
    0.57
    autism spectrum disorder

    Source sentences

    Summary
    only studies on autism spectrum disorder showed a significant combined effect size (d=0.57; N=68; 95% CI: 0.15-0.99; P<0.01).
    1 context sentence
    Summary · context
    In 19 clinical trials, covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress, the effects of OT administration were tested, with doses ranging from 15 IU to more than 7000 IU.
  3. 03HumanSystematic reviewEfficacy outcome

    In disorders other than autism spectrum disorder, the combined effect of oxytocin was not significant.

    In plain wordsIn pooled trials of disorders other than autism, oxytocin showed no significant combined benefit.

    Peptide
    Oxytocin
    Outcome
    No significant changeCombined effect of oxytocin in disorders other than autism
    Study

    n: not reported in source

    Outcome group
    Overall treatment effect · Mental health and mood
    Studied dose
    15 IU to more than 7000 IUAs given in this study (human).

    Source sentences

    Summary
    However, of all disorders, only studies on autism spectrum disorder showed a significant combined effect size (d=0.57; N=68; 95% CI: 0.15-0.99; P<0.01).
    1 context sentence
    Summary · context
    In 19 clinical trials, covering autism, social anxiety, postnatal depression, obsessive-compulsive problems, schizophrenia, borderline personality disorder and post-traumatic stress, the effects of OT administration were tested, with doses ranging from 15 IU to more than 7000 IU.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2/3NCT06248710

Dog Presence and Oxytocin on Trust Towards Therapists

Dr. Karin Hedigern = 17629 Jan 2024 to est. 31 Dec 2024

Depressive Symptoms · Human-Animal Interaction

Trial pageClinicalTrials.govUpdated 5 Nov 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.